Addex shareholders approve all resolutions at extraordinary general meeting

Ad hoc announcement pursuant to art. 53 lr  geneva, switzerland, december 20, 2023 - addex therapeutics (six: adxn and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development (“the company”), announced today that its shareholders approved, with a large majority, all of the proposals of the board of directors at its extraordinary general meeting (egm) held on december 19, 2023.
ADXN Ratings Summary
ADXN Quant Ranking